Over 36 percent of inspected drug-making units had to be shut: CDSCO chief
"The issues in the Indian pharma industry relate to "non-compliance which leads to quality issues," CDSCO Chief
Bengaluru: India's drug regulator reported that over 36 percent of the 400 drug manufacturing units inspected since last year have been directed to close. This action follows heightened scrutiny prompted by deaths associated with sub-standard cough syrups.
India, known as a global pharmaceutical hub due to its vast drug production, is actively working to rebuild trust after Indian-manufactured cough syrups were implicated in child deaths in Gambia, Uzbekistan, and Cameroon.
According to a Reuters report, India's Central Drugs Standard Control Organization (CDSCO) chief Rajeev Raghuvanshi said that after one and a half years of inspections, he was "not very happy to say that more than 36 per cent of them (manufacturing units) had to be closed."
The issues in the Indian pharma industry relate to "non-compliance which leads to quality issues," he told an event in Mumbai.
He did not elaborate or name any companies.
Cough syrups made in India and Indonesia have been linked to the deaths of more than 300 children globally. The medicines were found to contain high levels of two known toxins, diethylene glycol and ethylene glycol, leading to acute kidney injury and death.
India is the world's third largest maker of drugs by volume after the United States and China. India's pharma export sales are expected to reach $55 billion by 2030, according a government-backed trade body Pharmaceuticals Export Promotion Council of India (Pharmexcil). Export sales in 2023-2024 were $27.85 billion.
Prime Minister Narendra Modi's government late last year also issued revised guidelines to ensure compliance with global standards and made it mandatory for all of country's drug manufacturing units to adhere to them.
"We have not had any complaint from World Health Organization (WHO) or any other agency since last July .. we've been able to control the issues that were happening from a quality point of view," Raghuvanshi said.
Read also: Maiden Pharma denies tampering with tests in probe of cough syrup deaths
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd